Skip to Content
Merck
  • Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.

Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.

Cancer cell (2023-04-22)
Sujata Jana, Sandipan Brahma, Sonali Arora, Cynthia L Wladyka, Patrick Hoang, Steven Blinka, Rowan Hough, Jessie L Horn, Yuzhen Liu, Li-Jie Wang, Philippe Depeille, Eric Smith, Robert B Montgomery, John K Lee, Michael C Haffner, Funda Vakar-Lopez, Petros Grivas, Jonathan L Wright, Hung-Ming Lam, Peter C Black, Jeroen P Roose, Alexey G Ryazanov, Arvind R Subramaniam, Steven Henikoff, Andrew C Hsieh
ABSTRACT

We uncover a tumor-suppressive process in urothelium called transcriptional-translational conflict caused by deregulation of the central chromatin remodeling component ARID1A. Loss of Arid1a triggers an increase in a nexus of pro-proliferation transcripts, but a simultaneous inhibition of the eukaryotic elongation factor 2 (eEF2), which results in tumor suppression. Resolution of this conflict through enhancing translation elongation speed enables the efficient and precise synthesis of a network of poised mRNAs resulting in uncontrolled proliferation, clonogenic growth, and bladder cancer progression. We observe a similar phenomenon in patients with ARID1A-low tumors, which also exhibit increased translation elongation activity through eEF2. These findings have important clinical implications because ARID1A-deficient, but not ARID1A-proficient, tumors are sensitive to pharmacologic inhibition of protein synthesis. These discoveries reveal an oncogenic stress created by transcriptional-translational conflict and provide a unified gene expression model that unveils the importance of the crosstalk between transcription and translation in promoting cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-ARID1A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Y-27632 dihydrochloride, ≥98% (HPLC)
Sigma-Aldrich
Hydrocortisone, ≥98% (HPLC)
Sigma-Aldrich
Cycloheximide, from microbial, ≥94% (TLC)
Roche
cOmplete, Mini Protease Inhibitor Cocktail, Tablets provided in a glass vial
Sigma-Aldrich
Anti-α-Tubulin antibody, Mouse monoclonal, clone AA13, purified from hybridoma cell culture
Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Sigma-Aldrich
Tamoxifen, ≥99%
Sigma-Aldrich
Anti-acetyl-Histone H3 (Lys27) Antibody, clone RM172, clone RM172, from rabbit
Sigma-Aldrich
eEF2K Inhibitor, A-484954, The eEF2K Inhibitor, A-484954, also referenced under CAS 142557-61-7, controls the biological activity of eEF2K Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Sigma-Aldrich
Anti-Puromycin Antibody, clone 12D10, clone 12D10, from mouse